Analysts Set NovoCure Limited (NASDAQ:NVCR) Target Price at $32.83

NovoCure Limited (NASDAQ:NVCR – Get Free Report) has earned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among analysts that […]

Leave a Reply

Your email address will not be published.

Previous post OFA Group (NASDAQ:OFAL) Upgraded by Wall Street Zen to “Hold” Rating
Next post ServiceNow, Inc. (NYSE:NOW) Receives $1,062.50 Average Price Target from Brokerages